PLx Pharma (NASDAQ:PLXP) Shares Cross Below Two Hundred Day Moving Average of $4.85

PLx Pharma Inc (NASDAQ:PLXP) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.85 and traded as low as $1.96. PLx Pharma shares last traded at $1.99, with a volume of 34,780 shares changing hands.

Several equities analysts have recently issued reports on PLXP shares. Zacks Investment Research downgraded shares of PLx Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 14th. ValuEngine upgraded PLx Pharma from a “sell” rating to a “hold” rating in a research note on Monday, March 9th.

The firm has a market capitalization of $18.22 million, a P/E ratio of -0.61 and a beta of 4.58. The stock’s 50-day simple moving average is $4.78 and its 200-day simple moving average is $4.83.

An institutional investor recently bought a new position in PLx Pharma stock. University of Texas Texas AM Investment Managment Co. purchased a new stake in shares of PLx Pharma Inc (NASDAQ:PLXP) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 62,673 shares of the biotechnology company’s stock, valued at approximately $274,000. PLx Pharma comprises approximately 0.3% of University of Texas Texas AM Investment Managment Co.’s holdings, making the stock its 7th largest position. University of Texas Texas AM Investment Managment Co. owned approximately 0.68% of PLx Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 22.27% of the company’s stock.

About PLx Pharma (NASDAQ:PLXP)

PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.

See Also: What is Cost of Goods Sold (COGS)?

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.